Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4

被引:23
|
作者
Nakayama, Shin [1 ,2 ,3 ,4 ,5 ]
Amiry-Moghaddam, Mahmood [6 ]
Ottersen, Ole Petter [6 ]
Bhardwaj, Anish [1 ,2 ,3 ,4 ,7 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ, Dept Anesthesiol, Portland, OR 97201 USA
[4] Oregon Hlth & Sci Univ, Dept Perioperat Med, Portland, OR 97201 USA
[5] Univ Tsukuba, Dept Anesthesiol, Fac Med, Tsukuba, Ibaraki, Japan
[6] Univ Oslo, Inst Basic Med Sci, Oslo, Norway
[7] Univ Texas Med Branch, Dept Neurol, 9-128 John Sealy Annex,Route 0539,301 Univ Blvd, Galveston, TX 77555 USA
关键词
Conivaptan; Global cerebral ischemia; Cardiac arrest; Cerebral edema; Aquaporins; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; BLOOD-BRAIN-BARRIER; EXPERIMENTAL STROKE; HYPERTONIC SALINE; NERVOUS-SYSTEM; WATER-CONTENT; RAT-BRAIN; OSMOTHERAPY; MICE; ISCHEMIA;
D O I
10.1007/s12028-015-0236-4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background Cerebral edema is a major cause of mortality following cardiac arrest (CA) and cardiopulmonary resuscitation (CPR). Arginine vasopressin (AVP) and water channel aquaporin-4 (AQP4) have been implicated in the pathogenesis of CA-evoked cerebral edema. In this study, we examined if conivaptan, a V-1a and V-2 antagonist, attenuates cerebral edema following CA/CPR in wild type (WT) mice as well as mice with targeted disruption of the gene encoding alpha-syntrophin (alpha-syn(-/-)) that demonstrate diminished perivascular AQP4 pool. Methods Isoflurane-anesthetized adult male WT C57Bl/6 and alpha-syn(-/-) mice were subjected to 8 min CA/CPR and treated with either bolus IV injection (0.15 or 0.3 mg/kg) followed by continuous infusion of conivaptan (0.15 mg/kg/day or 0.3 mg/kg/day), or vehicle infusion for 48 h. Serum osmolality, regional brain water content, and blood-brain barrier (BBB) disruption were determined at the end of the experiment. Sham-operated mice in both strains served as controls. ResultsTreatment with conivaptan elevated serum osmolality in a dose-dependent manner. In WT mice, conivaptan at 0.3 mg dose significantly attenuated regional water content in the caudoputamen (81.0 +/- A 0.5 vs 82.5 +/- A 0.4 % in controls; mean +/- A SEM) and cortex (78.8 +/- A 0.2 vs 79.4 +/- A 0.2 % in controls), while conivaptan at 0.15 mg was not effective. In alpha-syn(-/-) mice, conivaptan at 0.3 mg dose did not attenuate water content compared with controls. Conivaptan (0.3 mg/kg/day) attenuated post-CA BBB disruption at 48 h in WT mice but not in alpha-syn(-/-) mice. Conclusions Continuous IV infusion of conivaptan attenuates cerebral edema and BBB disruption following CA. These effects of conivaptan that are dependent on the presence of perivascular pool of AQP4 appear be mediated via its dual effect on V-1 and V-2 receptors.
引用
收藏
页码:273 / 282
页数:10
相关论文
共 40 条
  • [1] Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Shin Nakayama
    Mahmood Amiry-Moghaddam
    Ole Petter Ottersen
    Anish Bhardwaj
    Neurocritical Care, 2016, 24 : 273 - 282
  • [2] Osmotherapy With Hypertonic Saline Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Nakayama, Shin
    Migliati, Elton
    Amiry-Moghaddam, Mahmood
    Ottersen, Ole P.
    Bhardwaj, Anish
    CRITICAL CARE MEDICINE, 2016, 44 (08) : E702 - E710
  • [3] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [4] Osmotherapy with Hypertonic Saline Ameliorates Cerebral Edema following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Nakayama, Shin
    Migliati, Elton
    Bhardwaj, Amish
    STROKE, 2009, 40 (04) : E221 - E221
  • [5] Conivaptan:: A dual vasopressin receptor V1a/V2 antagonist (vol 25, pg 261, 2007)
    不详
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (04): : 397 - 397
  • [6] Effect of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs
    Yatsu, T
    Kusayama, T
    Tomura, Y
    Arai, Y
    Aoki, M
    Tahara, A
    Wada, K
    Tsukada, J
    PHARMACOLOGICAL RESEARCH, 2002, 46 (05) : 375 - 381
  • [7] Na+-K+-2Cl- Cotransport Inhibitor Attenuates Cerebral Edema Following Experimental Stroke via the Perivascular Pool of Aquaporin-4
    Migliati, Elton R.
    Amiry-Moghaddam, Mahmood
    Froehner, Stanley C.
    Adams, Marvin E.
    Ottersen, Ole Petter
    Bhardwaj, Anish
    NEUROCRITICAL CARE, 2010, 13 (01) : 123 - 131
  • [8] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, M
    Thomas, I
    Ghali, JK
    Selaru, P
    Chanoine, F
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2001, 104 (20) : 2417 - 2423
  • [9] Arginine-Vasopressin V1 but not V2 Receptor Antagonism Modulates Infarct Volume, Brain Water Content, and Aquaporin-4 Expression Following Experimental Stroke
    Xiaoqin Liu
    Shin Nakayama
    Mahmood Amiry-Moghaddam
    Ole Petter Ottersen
    Anish Bhardwaj
    Neurocritical Care, 2010, 12 : 124 - 131
  • [10] Arginine-Vasopressin V1 but not V2 Receptor Antagonism Modulates Infarct Volume, Brain Water Content, and Aquaporin-4 Expression Following Experimental Stroke
    Liu, Xiaoqin
    Nakayama, Shin
    Amiry-Moghaddam, Mahmood
    Ottersen, Ole Petter
    Bhardwaj, Anish
    NEUROCRITICAL CARE, 2010, 12 (01) : 124 - 131